Hot Features
プレミアム
Biogen Inc (1BIIB)
BIT
登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Dapirolizumab pegol (DZP) met its...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd...
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference -New testing method highlights link...
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases The collaboration aims to...
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as...
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Robin Kramer, Chief Accounting Officer, to Succeed HimCAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE...
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 The detailed study results confirmed interim...
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB...
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study...
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients Designation is based on data from the...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -6.5 | -4.39040864573 | 148.05 | 148.05 | 141.45 | 20 | 145.649375 | DE |
| 4 | -12.05 | -7.84505208333 | 153.6 | 155.25 | 141.45 | 26 | 150.12649701 | DE |
| 12 | -29.35 | -17.1737858397 | 170.9 | 176.15 | 141.45 | 41 | 162.76057762 | DE |
| 26 | -66.65 | -32.0124879923 | 208.2 | 220.7 | 141.45 | 40 | 175.71127265 | DE |
| 52 | -79.65 | -36.0081374322 | 221.2 | 244.6 | 141.45 | 34 | 189.9013994 | DE |
| 156 | -74.05 | -34.3460111317 | 215.6 | 244.6 | 141.45 | 33 | 190.13146503 | DE |
| 260 | -74.05 | -34.3460111317 | 215.6 | 244.6 | 141.45 | 33 | 190.13146503 | DE |
al44
3分前
StockWorkOrange
3分前
jd757
5分前
TheKid5
7分前
Viagra_Bastard
7分前
PioneerPhoenix73
7分前
Cameron12221
7分前
Jackxkr
8分前
CaptBeer
8分前
Dingbatt
8分前
doc2016
9分前
BlazingStocks
9分前
BlazingStocks
9分前
alphapuppy
9分前
jd757
11分前
prototype_101
13分前
NASDAQ2020
13分前
Midwestrader
14分前
mrkirby
14分前
Pyramid2
15分前
glenn1919
17分前
glenn1919
17分前
Implanting
17分前
elks
22分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
